Regulatory Watch
Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market • Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list • Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs • Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence • Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California • Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent • Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone • Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples • Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion • Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' • Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open • Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. • June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease • Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends • Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed • Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief • Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited • Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 • Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited • Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts • 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 • Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market • Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list • Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs • Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence • Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California • Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent • Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone • Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples • Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion • Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' • Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open • Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. • June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease • Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends • Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed • Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief • Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited • Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 • Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited • Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts • 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022
Subscribe

Vendor Ratings

Independent ratings based on transparency, third-party testing, pricing, and regulatory compliance. Updated quarterly. Vendors cannot pay to improve their scores.

How We Rate

Each vendor is evaluated across 5 categories: transparency (25%), testing (25%), pricing (20%), reputation (15%), and compliance (15%). Letter grades reflect the weighted composite score. Read our full methodology

A-

Science.bio (Closed)

View full report →
Transparency
95
Testing
90
Value
70
Compliance
40
B+

Hims & Hers

View full report →
Transparency
80
Testing
75
Value
60
Compliance
90
B+

Peptide Partners

View full report →
Transparency
80
Testing
90
Value
55
Compliance
65
B

Eternal Peptides

View full report →
Transparency
70
Testing
80
Value
55
Compliance
60
B

Verified Peptides

View full report →
Transparency
75
Testing
75
Value
55
Compliance
60
B-

ProHealth Longevity

View full report →
Transparency
70
Testing
65
Value
60
Compliance
80
B-

Trident Peptides

View full report →
Transparency
55
Testing
50
Value
60
Compliance
55
C+

Integrative Peptides

View full report →
Transparency
40
Testing
55
Value
35
Compliance
45
C+

Infiniwell

View full report →
Transparency
45
Testing
50
Value
30
Compliance
50
C+

Paradigm Peptides

View full report →
Transparency
45
Testing
60
Value
50
Compliance
55
C+

Swisschems

View full report →
Transparency
50
Testing
55
Value
75
Compliance
40
C

Core Peptides

View full report →
Transparency
50
Testing
45
Value
55
Compliance
50
C

Limitless Life Nootropics

View full report →
Transparency
45
Testing
50
Value
55
Compliance
45
C-

Prime Peptides

View full report →
Transparency
50
Testing
55
Value
55
Compliance
25
C-

Strate Labs

View full report →
Transparency
50
Testing
60
Value
70
Compliance
20
D+

LVLUP Health

View full report →
Transparency
40
Testing
45
Value
50
Compliance
35
F

Amino Asylum

View full report →
Transparency
15
Testing
25
Value
70
Compliance
0
F

Biokey Research

View full report →
Transparency
5
Testing
5
Value
50
Compliance
10
F

Peptide Sciences

View full report →
Transparency
72
Testing
68
Value
55
Compliance
50
F

Tailor Made Compounding

View full report →
Transparency
20
Testing
25
Value
50
Compliance
5

Ratings reflect our independent analysis based on publicly available information and our documented methodology. Vendors cannot pay for favorable coverage or preview their ratings before publication. Full disclosure policy.